|Venture Capital Spending on Biotech|
In today's featured white paper, another very interesting point that author and analysis George Green brings up is the shifting trends of the capitol injected into the market by venture capitalists. After suffering from a steep setback in 2008, venture capitalists have only just started in re-investing in biotechs. Green also notes that the money is going to proven biotechs and those who have established products. As investments are growing, so is the investment in the research and development which is driving clinical supply and process development demand.
Read the complete white paper Challenging Outlook for Contract Manufacturers, download it here.
What this industry hasn't seen, Greene points out, is a string of mergers and acquisitions, much like the rest of the industry. Do you see this as a factor that will come up in the next few years?